1-12 of 12
Nathan Martin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Bruno Paiva, Irene Manrique, Ethan G. Thompson, Timothy B. Campbell, Camila Guerrero, Nathan Martin, Larry D Anderson, Jr., Jesus G Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, Philippe Moreau, Jesús F. San-Miguel, Nikhil C. Munshi, Shari Kaiser
Journal: Blood
Blood (2024) 144 (Supplement 1): 900.
https://doi.org/10.1182/blood-2024-203007
Published: 2024
Journal Articles

Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis

Debashree Basudhar, Dante Descalzi-Montoya, Hao Tang, Minshi Wang, Fan Wu, P. Leif Bergsagel, Xavier Leleu, Daniela Hosseyni, Maria Chaudhry, Nathan Martin, Ethan G. Thompson
Journal: Blood
Blood (2024) 144 (Supplement 1): 3382.
https://doi.org/10.1182/blood-2024-198740
Published: 2024
Journal Articles

Differences in Single Cells between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance Are Driven By Different Factors

Mehmet K. Samur, Nathan Martin, Ethan Thompson, Mariateresa Fulciniti, Anil Aktas-Samur, Shari Kaiser, Nikhil C Munshi
Journal: Blood
Blood (2022) 140 (Supplement 1): 2106–2107.
https://doi.org/10.1182/blood-2022-168903
Published: 2022
Journal Articles

Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival

Bruno Paiva, Irene Manrique, Julie A Rytlewski, Timothy B. Campbell, Christian Kazanecki, Nathan Martin, Shari M. Kaiser, Larry D. Anderson, Jr., Jesus Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, Philippe Moreau, Jesús San-Miguel, Nikhil C Munshi
Journal: Blood
Blood (2022) 140 (Supplement 1): 2104–2105.
https://doi.org/10.1182/blood-2022-166658
Published: 2022
Journal Articles

Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

Nina Shah, Nikhil C. Munshi, Jesús G. Berdeja, Sundar Jagannath, Olivia Finney, Nathan Martin, Amit Agarwal, Everton Rowe, Timothy B. Campbell, Jesús F. San-Miguel
Journal: Blood
Blood (2021) 138 (Supplement 1): 1739.
https://doi.org/10.1182/blood-2021-148375
Published: 2021
Journal Articles

KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, Jesús G. Berdeja, Paula Rodriguez-Otero, Damian J. Green, Sundar Jagannath, Sagar Lonial, Adrianna Gipson, Andrea Caia, Nathan Martin, Zhihong Yang, Gianfranco Pittari, Maria-Victoria Mateos
Journal: Blood
Blood (2021) 138 (Supplement 1): 4830.
https://doi.org/10.1182/blood-2021-147412
Published: 2021
Journal Articles

Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma

Noopur S. Raje, Nina Shah, Sundar Jagannath, Jonathan L. Kaufman, David S. Siegel, Nikhil C. Munshi, Jacalyn Rosenblatt, Yi Lin, Andrzej Jakubowiak, Alison Timm, Ashish Yeri, Nathan Martin, Timothy B. Campbell, Olivia Finney, Anna Truppel-Hartmann, Fabio Petrocca, Jesús G. Berdeja, Melissa Alsina
Journal: Blood
Blood (2021) 138 (Supplement 1): 548.
https://doi.org/10.1182/blood-2021-146518
Published: 2021
Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121) Responses Are Characterized By Early and Temporally Consistent Activation and Expansion of CAR T Cells with a T Effector Phenotype

Nathan Martin, PhD, Ethan G. Thompson, PhD, Will Brown, MS, Olivia Finney, PhD, Julie Rytlewski, PhD, Yue Jiang, PhD, Dipen Sangurdekar, PhD, Julie Wang, PharmD, PhD, Hans Bitter, PhD, Ronald J. Hause, Jr., PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Shari Kaiser, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-134378
Published: 2020
Journal Articles

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Olivia C Finney, Ashish Yeri, PhD, Pingping Mao, PhD, Chetanya Pandya, PhD, Eric Alonzo, PhD, Gregory Hopkins, BS, Sebastian Hymson, BS, Tiffany Hu, BS, Marianna Foos, MS, Sneha Bhadoriya, MS, Stephanie Hintzen, BS, Maple Gioia, MS, Alison Timm, MS, Monica Massaro, MPH, Ron Hause, PhD, Shari Kaiser, PhD, Nathan Martin, PhD, Melissa Alsina, MD, Nina Shah, MD, Noopur S. Raje, MD, Jesus G. Berdeja, MD, Shannon Grande, PhD, Hans Bitter, PhD, Fabio Petrocca, MD, Kevin M. Friedman, PhD, Dipen Sangurdekar, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-142426
Published: 2020
Journal Articles

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

Julie Rytlewski, PhD, Deepu Madduri, MD, Jaymes Fuller, PhD, Timothy B. Campbell, MD PhD, Afshin Mashadi-Hossein, MSc, Ethan G. Thompson, PhD, Yue Jiang, PhD, Nathan Martin, PhD, Dipen Sangurdekar, PhD, Olivia Finney, PhD, Hans Bitter, PhD, Amit Agarwal, MD PhD, Shari Kaiser, PhD, Kristen Hege, MD, Ronald J. Hause, Jr., PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-134369
Published: 2020
Journal Articles

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Melissa Alsina, MD, Nina Shah, MD, Noopur S. Raje, MD, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L. Kaufman, MD, David S. Siegel, MD PhD, Nikhil C. Munshi, MD, Jacalyn Rosenblatt, MD, Yi Lin, MD PhD, Andrzej Jakubowiak, MD PhD, Jagoda Jasielec, MD, Alison Timm, MS, Ashley Turka, Pingping Mao, PhD, Nathan Martin, PhD, Timothy B. Campbell, MD PhD, Kristen Hege, Hans Bitter, PhD, Fabio Petrocca, MD, Jesus G. Berdeja, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 25–26.
https://doi.org/10.1182/blood-2020-140410
Published: 2020
Journal Articles

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Ethan G. Thompson, PhD, Yue Jiang, PhD, Timothy B. Campbell, MD PhD, Jaymes Fuller, PhD, Shari Kaiser, PhD, Afshin Mashadi-Hossein, MSc, Julie Rytlewski, PhD, Nathan Martin, PhD, Olivia Finney, PhD, Katja Kleinsteuber, PhD, Eric Alonzo, PhD, Chetanya Pandya, PhD, Amit Agarwal, MD PhD, Kristen Hege, Noopur S. Raje, MD, Nikhil C. Munshi, MD, Ronald J. Hause, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4328.
https://doi.org/10.1182/blood-2019-124998
Published: 2019